Timo Purmonen

445 total citations
24 papers, 321 citations indexed

About

Timo Purmonen is a scholar working on Economics and Econometrics, Psychiatry and Mental health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Timo Purmonen has authored 24 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Economics and Econometrics, 7 papers in Psychiatry and Mental health and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Timo Purmonen's work include Migraine and Headache Studies (5 papers), Renal cell carcinoma treatment (5 papers) and Spondyloarthritis Studies and Treatments (4 papers). Timo Purmonen is often cited by papers focused on Migraine and Headache Studies (5 papers), Renal cell carcinoma treatment (5 papers) and Spondyloarthritis Studies and Treatments (4 papers). Timo Purmonen collaborates with scholars based in Finland, China and India. Timo Purmonen's co-authors include Janne Martikainen, Vesa Kataja, Mariann I. Lassenius, Iiro Toppila, Erkki Soini, Samu Kurki, Christian Asseburg, Pirkko‐Liisa Kellokumpu‐Lehtinen, Minna A. Korolainen and M. Nissilä and has published in prestigious journals such as Alzheimer s & Dementia, Clinical Therapeutics and Medical Decision Making.

In The Last Decade

Timo Purmonen

23 papers receiving 316 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Timo Purmonen Finland 12 96 79 74 62 49 24 321
Meera M. Dhodapkar United States 9 52 0.5× 14 0.2× 37 0.5× 88 1.4× 26 0.5× 57 393
Per-Olof Thuresson Switzerland 8 97 1.0× 11 0.1× 98 1.3× 85 1.4× 31 0.6× 22 390
Mirza I. Rahman United States 10 41 0.4× 32 0.4× 48 0.6× 43 0.7× 32 0.7× 18 379
Anju Parthan United States 11 57 0.6× 15 0.2× 81 1.1× 129 2.1× 39 0.8× 38 469
John J. Ko United States 11 102 1.1× 17 0.2× 46 0.6× 31 0.5× 100 2.0× 23 443
Heather Burney United States 11 15 0.2× 45 0.6× 63 0.9× 95 1.5× 28 0.6× 42 390
April Barbour United States 5 40 0.4× 20 0.3× 72 1.0× 267 4.3× 46 0.9× 7 494
Andrea Leith United Kingdom 9 47 0.5× 16 0.2× 139 1.9× 64 1.0× 18 0.4× 24 467
Antonella Pedrini Italy 9 46 0.5× 45 0.6× 32 0.4× 15 0.2× 34 0.7× 50 248

Countries citing papers authored by Timo Purmonen

Since Specialization
Citations

This map shows the geographic impact of Timo Purmonen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timo Purmonen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timo Purmonen more than expected).

Fields of papers citing papers by Timo Purmonen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timo Purmonen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timo Purmonen. The network helps show where Timo Purmonen may publish in the future.

Co-authorship network of co-authors of Timo Purmonen

This figure shows the co-authorship network connecting the top 25 collaborators of Timo Purmonen. A scholar is included among the top collaborators of Timo Purmonen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timo Purmonen. Timo Purmonen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Purmonen, Timo, Samu Kurki, Minna A. Korolainen, et al.. (2021). Erenumab Decreases Headache-Related Sick Leave Days and Health Care Visits: A Retrospective Real-World Study in Working Patients with Migraine. Neurology and Therapy. 11(1). 223–235. 9 indexed citations
4.
Korolainen, Minna A., Samuli Tuominen, Samu Kurki, et al.. (2020). Burden of migraine in Finland: multimorbidity and phenotypic disease networks in occupational healthcare. The Journal of Headache and Pain. 21(1). 8–8. 15 indexed citations
5.
Huusko, Jenni, Timo Purmonen, Iiro Toppila, Mariann I. Lassenius, & Heikki Ukkonen. (2020). Real-World Clinical Diagnostics of Heart Failure Patients With Reduced or Preserved Ejection Fraction. ESC Heart Failure. 7(3). 1039–1048. 15 indexed citations
6.
Purmonen, Timo, et al.. (2019). <p>Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland</p>. ClinicoEconomics and Outcomes Research. Volume 11. 159–168. 9 indexed citations
7.
Korolainen, Minna A., Samu Kurki, Mariann I. Lassenius, et al.. (2019). Burden of migraine in Finland: health care resource use, sick-leaves and comorbidities in occupational health care. The Journal of Headache and Pain. 20(1). 13–13. 31 indexed citations
8.
Huusko, Jenni, Samu Kurki, Iiro Toppila, et al.. (2019). Heart Failure in Finland: Clinical Characteristics, Mortality, and Healthcare Resource Use. ESC Heart Failure. 6(4). 603–612. 13 indexed citations
9.
Turpeenniemi‐Hujanen, Taina, Antti Jekunen, Vesa Kataja, et al.. (2019). Sunitinib First-line Treatment in Metastatic Renal Cell Carcinoma: Costs and Effects. Anticancer Research. 39(10). 5559–5564. 13 indexed citations
10.
Purmonen, Timo, et al.. (2018). Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective. Cost Effectiveness and Resource Allocation. 16(1). 56–56. 9 indexed citations
11.
Purmonen, Timo, et al.. (2018). Budget impact analysis of secukinumab versus adalimumab in the treatment of ankylosing spondylitis. Journal of Medical Economics. 22(2). 151–157. 6 indexed citations
12.
13.
Purmonen, Timo, et al.. (2015). Budget Impact Analysis of Warfarin Reversal Therapies Among Hip Fracture Patients in Finland. Drugs in R&D. 15(1). 155–162. 4 indexed citations
14.
Asseburg, Christian, et al.. (2012). COST-EFFECTIVENESS OF ORAL TRIPTANS FOR ACUTE MIGRAINE: MIXED TREATMENT COMPARISON. International Journal of Technology Assessment in Health Care. 28(4). 382–389. 8 indexed citations
15.
Peura, P, et al.. (2011). [Indirect comparison and network meta-analyses--new tools for the assessment of evidence on the relative efficacy of drugs].. PubMed. 127(9). 900–10. 1 indexed citations
16.
17.
Peura, P, et al.. (2011). Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans. Medical Decision Making. 32(2). 237–245. 16 indexed citations
18.
Purmonen, Timo, et al.. (2010). Current and predicted cost of metastatic renal cell carcinoma in Finland. Acta Oncologica. 49(6). 837–843. 15 indexed citations
19.
Purmonen, Timo, Päivi Auvinen, & Janne Martikainen. (2010). Budget impact analysis of trastuzumab in early breast cancer: A hospital district perspective. International Journal of Technology Assessment in Health Care. 26(2). 163–169. 11 indexed citations
20.
Purmonen, Timo, et al.. (2008). Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clinical Therapeutics. 30(2). 382–392. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meera M. Dhodapkar Breakdown of academic impact, for papers by Per-Olof Thuresson Breakdown of academic impact, for papers by Mirza I. Rahman Breakdown of academic impact, for papers by Anju Parthan Breakdown of academic impact, for papers by John J. Ko Breakdown of academic impact, for papers by Heather Burney Breakdown of academic impact, for papers by April Barbour Breakdown of academic impact, for papers by Andrea Leith Breakdown of academic impact, for papers by Antonella Pedrini
Rankless by CCL
2026